What is Ascletis Pharma's ASC30 being studied for?

ASC30 is being studied as a treatment for type 2 diabetes mellitus and also has potential for obesity and other metabolic diseases.

When will the results from the ASC30 Phase II study be available?

Topline results from the US Phase II study of ASC30 are expected in the third quarter of 2026.

What is the primary goal of the ASC30 Phase II trial?

The primary goal of the ASC30 Phase II trial is to evaluate the safety, tolerability, and efficacy of ASC30 tablets, specifically measuring the mean change in HbA1c at 13 weeks compared to placebo.

Home / Health / Diabetes Drug ASC30 Completes US Phase II Trial

Diabetes Drug ASC30 Completes US Phase II Trial

27 Apr

•

Summary

Ascletis Pharma's ASC30, an oral GLP-1 agonist, finished its US Phase II study.
The trial evaluated safety, tolerability, and efficacy for type 2 diabetes.
Topline results are anticipated in the third quarter of 2026.

Diabetes Drug ASC30 Completes US Phase II Trial

Ascletis Pharma has announced the completion of subject enrollment in its 13-week US Phase II study for ASC30, an investigational oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes mellitus (T2DM).

The multi-center, randomized, double-blind, placebo-controlled trial involved 100 participants across the United States. It was designed to evaluate the safety, tolerability, and efficacy of ASC30 tablets, with a primary endpoint measuring the mean change in HbA1c compared to a placebo after 13 weeks.